Weekly Report: what happened at SRDX last week (0520-0524)?
Weekly Report · 14h ago
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
NASDAQ · 05/20 14:49
Weekly Report: what happened at SRDX last week (0513-0517)?
Weekly Report · 05/20 09:00
Weekly Report: what happened at SRDX last week (0506-0510)?
Weekly Report · 05/13 09:00
Weekly Report: what happened at SRDX last week (0429-0503)?
Weekly Report · 05/06 09:00
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
NASDAQ · 05/03 17:12
Surmodics Price Target Maintained With a $71.00/Share by Barrington Research
Dow Jones · 05/02 18:35
Surmodics Is Maintained at Outperform by Barrington Research
Dow Jones · 05/02 18:35
Barrington Research Maintains Outperform on Surmodics, Maintains $71 Price Target
Benzinga · 05/02 18:26
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
TipRanks · 05/02 13:20
Reuters · 05/02 13:03
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
Surmodics's (NASDAQ:SRDX) returns on capital employed are 11%. Surmodics has a growing rate of return of 11%. The company has increased its return on capital over the last five years to 11%. This is a good rate of returns for a medical equipment company. The company could be worth looking at for its potential to grow over the long term.
Simply Wall St · 05/02 11:27
Reuters · 05/02 08:24
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Mastercard, Metagenomi, Ziff Davis and 3M among companies. Analyst cuts target price to $510 from $520 for Mastercard. 3M raises price objective to $105 from $100.
Reuters · 05/02 07:12
SurModics Up Nearly 31%, On Track for Largest Percent Increase Since July 2000 -- Data Talk
SurModics, Inc. ( SRDX ) is currently at $33.64, up $7.95 or 30.95%. Would be highest close since Feb. 12, 2024, when it closed at $34.08. On pace for largest percent increase since July 6, 2000. Down 7.46% year-to-date.
Dow Jones · 05/01 18:43
Surmodics Price Target Cut to $43.00/Share From $47.00 by Needham
Dow Jones · 05/01 18:38
Needham Maintains Buy on Surmodics, Lowers Price Target to $43
Benzinga · 05/01 18:28
SurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
TipRanks · 05/01 18:06
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Advanced Micro Devices, Inc. Shares dipped 6.9% to $147.44 on Wednesday. The company reported first-quarter results and issued revenue guidance for the second quarter. Shares of cannabis-related stocks traded higher following reports suggesting DEA plans to reclassify cannabis as a less dangerous drug.
Benzinga · 05/01 17:01
12 Health Care Stocks Moving In Wednesday's Intraday Session
CytomX Therapeutics stock increased by 154.6% to $4.15 during Wednesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 36.79%. CVRx and Mobile-health Network among the losers.
Benzinga · 05/01 16:31
Webull provides a variety of real-time SRDX stock news. You can receive the latest news about Surmodics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRDX
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.